At a glance
ClinicalIndex Comparison RecordN/ACompleted· 205 enrolled
Drug / intervention
EVO ICLdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Post-Market Evaluation of the EVO ICL
In Brief
A clinical study evaluating EVO ICL for Myopia and Myopic Astigmatism. Completed, enrolled 205 participants across 8 sites.
Detailed Summary
The objective of this study is to assess the rate of early intraocular pressure (IOP) increases following implantation of EVO/EVO+ Implantable Collamer Lens (ICL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyopia, Myopic Astigmatism
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2023202420252026
First PostedSep 2022
Enrollment StartSep 2022
Primary CompletionSep 2023
Study CompletionOct 2023
TodayJul 2026
First PostedSep 14, 2022
Enrollment StartSep 23, 2022
Primary CompletionSep 21, 2023
Study CompletionOct 4, 2023
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 3.8 years ago
Interventions
EVO ICLdevice
The EVO ICL is intended to be implanted within the posterior chamber, directly behind the iris, and in front of the anterior capsule of the human crystalline lens.